Literature DB >> 2789076

Enzyme kinetic and spectroscopic studies of inhibitor and effector interactions with indoleamine 2,3-dioxygenase. 1. Norharman and 4-phenylimidazole binding to the enzyme as inhibitors and heme ligands.

M Sono1, S G Cady.   

Abstract

The effects of norharman, one of the few known inhibitors of the heme protein indoleamine 2,3-dioxygenase, and of 4-phenylimidazole (4-PheImid), a heme ligand, on the catalytic (Vmax, Km) and spectroscopic properties (optical absorption, CD, and magnetic CD) of the rabbit small intestinal dioxygenase were investigated. Assays were performed with the substrate L- or D-tryptophan (Trp) and an ascorbic acid-methylene blue cofactor system at 25 degrees C. This study has revealed that both norharman and 4-PheImid exhibit noncompetitive inhibition with respect to L-Trp and D-Trp. The binding of norharman to the enzyme results in the formation of a low-spin complex in both the ferric and ferrous enzyme with comparable dissociation constants (Kd = approximately 10 microM at pH 7.0) that are about 10 times smaller than the observed Ki value. L-Trp exerts no effect for the ferric enzyme and slight negative cooperative effects for the ferrous enzyme on norharman binding. Close spectral similarities are observed between the adducts of the enzyme with norharman and 4-PheImid in the respective oxidation states. This, together with competition experiments using cyanide, demonstrates that norharman binds directly to the heme iron of the enzyme as a nitrogen donor ligand. Thus, norharman competes with O2 for the heme iron of the ferrous (active) enzyme, resulting in the observed inhibition. L-Trp and 4-PheImid appear to compete for the heme binding site in the ferric enzyme and display slight negative cooperativity on binding to the ferrous enzyme.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2789076     DOI: 10.1021/bi00439a012

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  20 in total

Review 1.  Tryptophan kynurenine metabolism as a common mediator of genetic and environmental impacts in major depressive disorder: the serotonin hypothesis revisited 40 years later.

Authors:  Gregory F Oxenkrug
Journal:  Isr J Psychiatry Relat Sci       Date:  2010       Impact factor: 0.481

2.  Interferon-gamma-inducible kynurenines/pteridines inflammation cascade: implications for aging and aging-associated psychiatric and medical disorders.

Authors:  Gregory F Oxenkrug
Journal:  J Neural Transm (Vienna)       Date:  2010-09-02       Impact factor: 3.575

3.  O-alkylhydroxylamines as rationally-designed mechanism-based inhibitors of indoleamine 2,3-dioxygenase-1.

Authors:  William P Malachowski; Maria Winters; James B DuHadaway; Ariel Lewis-Ballester; Shorouk Badir; Jenny Wai; Maisha Rahman; Eesha Sheikh; Judith M LaLonde; Syun-Ru Yeh; George C Prendergast; Alexander J Muller
Journal:  Eur J Med Chem       Date:  2015-12-17       Impact factor: 6.514

Review 4.  Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.

Authors:  Xiu-Xiu Wang; Si-Yu Sun; Qing-Qing Dong; Xiao-Xiang Wu; Wei Tang; Ya-Qun Xing
Journal:  Medchemcomm       Date:  2019-08-15       Impact factor: 3.597

5.  Structure-activity study of brassinin derivatives as indoleamine 2,3-dioxygenase inhibitors.

Authors:  Paul Gaspari; Tinku Banerjee; William P Malachowski; Alexander J Muller; George C Prendergast; James DuHadaway; Shauna Bennett; Ashley M Donovan
Journal:  J Med Chem       Date:  2006-01-26       Impact factor: 7.446

6.  Structure based development of phenylimidazole-derived inhibitors of indoleamine 2,3-dioxygenase.

Authors:  Sanjeev Kumar; Daniel Jaller; Bhumika Patel; Judith M LaLonde; James B DuHadaway; William P Malachowski; George C Prendergast; Alexander J Muller
Journal:  J Med Chem       Date:  2008-07-30       Impact factor: 7.446

7.  Identification of Potent Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors Based on a Phenylimidazole Scaffold.

Authors:  Michael G Brant; Jake Goodwin-Tindall; Kurt R Stover; Paul M Stafford; Fan Wu; Autumn R Meek; Paolo Schiavini; Stephanie Wohnig; Donald F Weaver
Journal:  ACS Med Chem Lett       Date:  2018-01-11       Impact factor: 4.345

8.  Crystallization and preliminary crystallographic studies of human indoleamine 2,3-dioxygenase.

Authors:  Shun-ichiro Oda; Hiroshi Sugimoto; Tadashi Yoshida; Yoshitsugu Shiro
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2006-02-10

9.  Inhibition of the aryl hydrocarbon receptor prevents Western diet-induced obesity. Model for AHR activation by kynurenine via oxidized-LDL, TLR2/4, TGFβ, and IDO1.

Authors:  Benjamin J Moyer; Itzel Y Rojas; Joanna S Kerley-Hamilton; Haley F Hazlett; Krishnamurthy V Nemani; Heidi W Trask; Rachel J West; Leslie E Lupien; Alan J Collins; Carol S Ringelberg; Barjor Gimi; William B Kinlaw; Craig R Tomlinson
Journal:  Toxicol Appl Pharmacol       Date:  2016-03-25       Impact factor: 4.219

Review 10.  Discovery of IDO1 Inhibitors: From Bench to Bedside.

Authors:  George C Prendergast; William P Malachowski; James B DuHadaway; Alexander J Muller
Journal:  Cancer Res       Date:  2017-12-15       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.